title: Guidelines for the medical treatment of idiopathic pulmonary fibrosis.
abstract: Idiopathic pulmonary fibrosis is defined as chronic fibrosing interstitial pneumonia limited to the lung, with poor prognosis. The incidence has been rising in recent years probably due to improved diagnostic methods and increased life expectancy. In 2013, the SEPAR guidelines for the diagnosis and treatment for idiopathic pulmonary fibrosis were published. Since then, clinical trials and meta-analyses have shown strong scientific evidence for the use of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis. In 2015, the international consensus of 2011 was updated and new therapeutic recommendations were established, prompting us to update our recommendation for the medical treatment of idiopathic pulmonary fibrosis accordingly. Diagnostic aspects and non-pharmacological treatment will not be discussed as no relevant developments have emerged since the 2013 guidelines.
authors.affiliation: Servicio de Neumología, Hospital Clínic, Barcelona, España; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), España. Electronic address: axaubetmir@gmail.com.
authors.forename: Antoni
authors.initials: A
authors.lastname: Xaubet
authors.affiliation: Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), España; Unidad Funcional del Intersticio Pulmonar (UFIP), Servicio de Neumología, Hospital Universitario de Bellvitge-Instituto de Investigación Biomédica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, España.
authors.forename: María
authors.initials: M
authors.lastname: Molina-Molina
authors.affiliation: Servicio de Neumología, Hospital Universitario de Canarias, Santa Cruz de Tenerife, España.
authors.forename: Orlando
authors.initials: O
authors.lastname: Acosta
authors.affiliation: Servicio de Neumología, Complejo Asistencial Universitario de León, León, España.
authors.forename: Elena
authors.initials: E
authors.lastname: Bollo
authors.affiliation: Servicio de Neumología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
authors.forename: Diego
authors.initials: D
authors.lastname: Castillo
authors.affiliation: Servicio de Neumología, Consorcio Hospital General Universitario de Valencia, Valencia, España.
authors.forename: Estrella
authors.initials: E
authors.lastname: Fernández-Fabrellas
authors.affiliation: Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), España; Servicio de Neumología, Hospital Universitario Virgen del Rocío, Sevilla, España.
authors.forename: José Antonio
authors.initials: JA
authors.lastname: Rodríguez-Portal
authors.affiliation: Servicio de Neumología, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, España.
authors.forename: Claudia
authors.initials: C
authors.lastname: Valenzuela
authors.affiliation: Servicio de Neumología, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, España.
authors.forename: Julio
authors.initials: J
authors.lastname: Ancochea
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D018450:Disease Progression; D018572:Disease-Free Survival; D019317:Evidence-Based Medicine; D005764:Gastroesophageal Reflux / Q000150:complications / Q000628:therapy; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications; D054990:Idiopathic Pulmonary Fibrosis / Q000150:complications / Q000188:drug therapy*; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D015201:Meta-Analysis as Topic; D011656:Pulmonary Emphysema / Q000150:complications; D011728:Pyridones / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012955:Societies, Medical / Q000592:standards; D013030:Spain
chemical_list: D000305:Adrenal Cortex Hormones; D007211:Indoles; D011728:Pyridones; C093844:pirfenidone; C530716:nintedanib
keywords: Fibrosis pulmonar idiopática; Idiopathic pulmonary fibrosis; Nintedanib; Pirfenidona; Pirfenidone; Tratamiento; Treatment